For NSCLC, the combinations of KRAS G12C inhibitors with afatinib (32), SHP2 inhibitors (33, 34), MEK inhibitors (35, 36), immunotherapies (38–40), and chemotherapy (41) have been reported. Here, KRAS is linked to non-small cell lung carcinoma.